1) Fexinidazole
非昔硝唑
2) Oxiconazole
硝酸奥昔康唑
3) tioxidazole
噻昔达唑
4) oxiconazole
奥昔康唑
5) Refecoxib
罗非昔布
1.
Evidence-Based Safety Reassessment of Post Marketed Drug — Importance of Recall of Refecoxib;
应重视上市后药物安全性的循证医学再评价——罗非昔布召回的意义
2.
A clinical study of Refecoxib and antibiotics for treatment of chronic prostatitis;
罗非昔布联合抗生素治疗慢性前列腺炎
6) rofecoxib
罗非昔布
1.
Analysis of withdrawal of rofecoxib-cyclooxygenase-2 specific inhibitor;
高选择性COX-2抑制剂罗非昔布撤市分析
2.
Effect of selective cyclooxygenase-2 inhibitor rofecoxib on the growth of human carcinoma of gallbladder;
选择性环氧合酶-2抑制剂罗非昔布对胆囊癌生长的影响
3.
Effect of rofecoxib on expressions of VEGF and inducible NOS in human gastric carcinoma tissues established in nude mice by orthotopic transplantation;
罗非昔布对裸鼠人胃癌原位种植瘤组织中血管内皮生长因子和诱导型一氧化氮合酶表达的影响
补充资料：硝酸奥昔康唑
分子式：C18H13N3OCL4·HNO3
分子量：暂无
CAS号：64211-45-6
性质：暂无
制备方法：暂无
用途：为新一代咪唑类抗真菌原料药。
分子量：暂无
CAS号：64211-45-6
性质：暂无
制备方法：暂无
用途：为新一代咪唑类抗真菌原料药。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条